focus -WSS

focus

author：leisure time 2025-10-01 10:57:34 - browse：1154

Illustration fo a pink arrow pointing downward. -- biotech coverage from STAT — Adobe

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%.

That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development. Ventyx said it would end work on the drug, which targets the signaling molecule TYK2, as a treatment for psoriasis and psoriatic arthritis.

Shares in Ventyx plummeted from $14.09 at market close to as little as $2.72 during after-hours trading. In the process, the company’s market value dropped from $830 million to around $160 million. Ventyx is now trading below its cash balance, which was $300 million as of the end of September.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Hospitals use virtual reality to design more inclusive rooms for kids

leisure time

WSS

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

Biden praises World Series champion Astros for impact off the field during White House celebration

Ohioans vote in high

Chinese researcher claims birth of first gene

Erich Jarvis studies song birds to learn about human stuttering

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

explore

focus

focus

Continuity nursing helped my family in our darkest PICU moments

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

After affirmative action ruling, medical educators look to 'holistic review'

Cancer, immunology, HIV research ensnared in fetal tissue politics

Guidelines to prevent youth baseball injuries need more muscle

Cheesesteak restaurant owner explains his secret sauce, the viral Malibu Barbie Dream Drizzle

Trump demands the U.S. pay no more for drugs than other countries … again

In venture capital firm's success, lessons for turning crisis into profit

FDA approval of Sarepta Duchenne genetic therapy gives me hope

CRISPR technology availability, affordability needs to be expanded

focus

More regulation could be coming for drug ads

'Patient friction coefficient' can gauge a clinical trial's patient burden

Cancer, immunology, HIV research ensnared in fetal tissue politics

Texas board proposes rules on abortion law emergency exemption

Wegovy cuts risk of cardiovascular events by 20%, study finds

Bring on the sabbaticals for nurses

hotspot

leisure time

focus

knowledge